CM
VERA icon

Crestline Management’s Vera Therapeutics VERA Stock Holding History

Crestline Management’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-160,347
Closed -$6.78M – 624
2024
Q4 		$6.78M Buy
160,347
+79,032
+97% +$3.5M 0.23% 99
2024
Q3 		$3.59M Buy
81,315
+17,765
+28% +$674K 0.19% 134
2024
Q2 		$2.3M Buy
63,550
+11,958
+23% +$474K 0.18% 125
2024
Q1 		$2.22M Sell
51,592
-8,477
-14% -$302K 0.2% 126
2023
Q4 		$924K Buy
60,069
+14,689
+32% +$187K 0.08% 150
2023
Q3 		$622K Hold
45,380
– – 0.07% 135
2023
Q2 		$728K Buy
45,380
+16,013
+55% +$145K 0.08% 146
2023
Q1 		$228K Buy
+29,367
New +$227K 0.03% 152

Other funds holding VERA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Crestline Management's VERA Position: Q1 2025 in Review

Crestline Management sold out of Vera Therapeutics (VERA) in Q1 2025, closing a stake of 160,347 shares — an estimated $6.78M sold.

Crestline Management first reported a position in VERA in Q1 2023 and held it in 8 quarters. The position peaked at $6.78M in Q4 2024. 179 funds tracked by Wall St. Rank hold VERA as of Q1 2025.

  • Crestline Management reported no remaining Vera Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Crestline Management sold 160,347 Vera Therapeutics shares in Q1 2025, an estimated $6.78M.
  • Crestline Management first reported a position in Vera Therapeutics in Q1 2023 and held it in 8 quarters.
  • Crestline Management's Vera Therapeutics position peaked at $6.78M in Q4 2024.
  • 179 funds tracked by Wall St. Rank held Vera Therapeutics as of Q1 2025.

Based on Crestline Management's 13F filing for Q1 2025, filed 15 May 2025.